Identifying bronchoconstriction from the ratio of diaphragm EMG to tidal volume.


Journal

Respiratory physiology & neurobiology
ISSN: 1878-1519
Titre abrégé: Respir Physiol Neurobiol
Pays: Netherlands
ID NLM: 101140022

Informations de publication

Date de publication:
09 2021
Historique:
received: 28 12 2020
revised: 09 05 2021
accepted: 16 05 2021
pubmed: 22 5 2021
medline: 21 1 2022
entrez: 21 5 2021
Statut: ppublish

Résumé

A fall of ≥ 20 % in forced expiratory volume in the first second (FEV1) with a cumulative dose of histamine ≤ 7.8 μmol is considered to indicate bronchial hyperactivity, but no method exists for patients who cannot perform spirometry properly. Here we hypothesized that increases in respiratory central output measured by chest wall electromyography of the diaphragm (EMGdi-c) expressed as a function of tidal volume (EMGdi-c/VT) would have discriminative power to detect a 'positive' challenge test. In a physiological study EMGdi was recorded from esophageal electrode (EMGdi-e) in 16 asthma patients and 16 healthy subjects during a histamine challenge test. In a second study, EMGdi from chest wall surface electrodes (EMGdi-c) was measured during a histamine challenge in 44 asthma patients and 51 healthy subjects. VT was recorded from a digital flowmeter during both studies. With histamine challenge test the change in EMGdi-e/VT in patients with asthma was significantly higher than that in healthy subjects (104.2 % ± 48.6 % vs 0.03 % ± 17.1 %, p < 0.001). Similarly there was a significant difference in the change of EMGdi-c/VT between patients with asthma and healthy subjects (90.5 % ± 75.5 % vs 2.4 % ± 21.7 %, p < 0.001). At the optimal cut-off point (29 % increase in EMGdi-c/VT), the area under the ROC curve (AUC) for detection of a positive test was 0.91 (p < 0.001) with sensitivity 86 % and specificity 92 %. We conclude that EMGdi-c/VT may be used as an alternative for the assessment of bronchial hypersensitivity and airway reversibility to differentiate patients with asthma from healthy subjects.

Sections du résumé

BACKGROUND
A fall of ≥ 20 % in forced expiratory volume in the first second (FEV1) with a cumulative dose of histamine ≤ 7.8 μmol is considered to indicate bronchial hyperactivity, but no method exists for patients who cannot perform spirometry properly. Here we hypothesized that increases in respiratory central output measured by chest wall electromyography of the diaphragm (EMGdi-c) expressed as a function of tidal volume (EMGdi-c/VT) would have discriminative power to detect a 'positive' challenge test.
METHODS
In a physiological study EMGdi was recorded from esophageal electrode (EMGdi-e) in 16 asthma patients and 16 healthy subjects during a histamine challenge test. In a second study, EMGdi from chest wall surface electrodes (EMGdi-c) was measured during a histamine challenge in 44 asthma patients and 51 healthy subjects. VT was recorded from a digital flowmeter during both studies.
RESULTS
With histamine challenge test the change in EMGdi-e/VT in patients with asthma was significantly higher than that in healthy subjects (104.2 % ± 48.6 % vs 0.03 % ± 17.1 %, p < 0.001). Similarly there was a significant difference in the change of EMGdi-c/VT between patients with asthma and healthy subjects (90.5 % ± 75.5 % vs 2.4 % ± 21.7 %, p < 0.001). At the optimal cut-off point (29 % increase in EMGdi-c/VT), the area under the ROC curve (AUC) for detection of a positive test was 0.91 (p < 0.001) with sensitivity 86 % and specificity 92 %.
CONCLUSIONS
We conclude that EMGdi-c/VT may be used as an alternative for the assessment of bronchial hypersensitivity and airway reversibility to differentiate patients with asthma from healthy subjects.

Identifiants

pubmed: 34020067
pii: S1569-9048(21)00077-X
doi: 10.1016/j.resp.2021.103692
pii:
doi:

Substances chimiques

Bronchodilator Agents 0
Histamine 820484N8I3

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

103692

Informations de copyright

Copyright © 2021. Published by Elsevier B.V.

Auteurs

Bai-Ting He (BT)

State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, China.

Ying-Mei Luo (YM)

State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, China.

Li-Shuang Wang (LS)

State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, China.

Yong-Yi Chen (YY)

State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, China.

Caroline Jolley (C)

Faculty of Life Sciences and Medicine, King's College London School of Medicine, London, UK.

Joerg Steier (J)

Faculty of Life Sciences and Medicine, King's College London School of Medicine, London, UK.

John Moxham (J)

Faculty of Life Sciences and Medicine, King's College London School of Medicine, London, UK.

Michael L Polkey (ML)

Respiratory Muscle Laboratory, the Royal Brompton Hospital, London, UK.

Yuanming Luo (Y)

State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, China; Faculty of Life Sciences and Medicine, King's College London School of Medicine, London, UK; Adelaide Institute for Sleep Health, College of Medicine and Public Health, Flinders University, Australia. Electronic address: Yuanmingluo9431@yahoo.co.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH